Management of Scalp Psoriasis: Current Perspectives

Overview

Journal Psoriasis (Auckl)

Publisher Dove Medical Press

Date 2018 Feb 2

PMID 29387592

Citations 13

Authors

Kim Blakely

Melinda Gooderham

Affiliations

Soon will be listed here.

Abstract

Psoriasis is a chronic inflammatory condition. The age of onset, chronicity, physical, and psychosocial consequences of the disease cause psoriasis to have a significant impact on patient quality of life. Scalp psoriasis is no different, and effective treatment results in an improvement in quality of life. Successful management of scalp psoriasis includes topical therapies that are acceptable to the patient for mild-to-moderate disease, and systemic therapies for recalcitrant or moderate-to-severe disease. The most effective topical therapies are corticosteroid products, or combination products with calcipotriol and corticosteroid. Newer vehicle options provide more attractive and pleasing products for patients and may improve adherence. The current perspectives for management of scalp psoriasis are discussed including available data for systemic therapy of severe disease.

Citing Articles

Updates on Psoriasis in Special Areas.

Butacu A, Toma C, Negulet I, Manole I, Banica A, Plesea A J Clin Med. 2025; 13(24.

PMID: 39768472 PMC: 11728371. DOI: 10.3390/jcm13247549.

Comparison of adalimumab with methotrexate for psoriasis: A meta-analysis of randomized controlled studies.

Yang X, Liu Y Medicine (Baltimore). 2024; 103(32):e37216.

PMID: 39121282 PMC: 11315506. DOI: 10.1097/MD.0000000000037216.

A narrative review of fixed combination calcipotriol/betamethasone aerosol foam (Enstilar) in the management of psoriasis with scalp involvement.

Staubach P, Korber A, Trueb R, Mann C, von Kiedrowski R Drugs Context. 2024; 13.

PMID: 38770372 PMC: 11104291. DOI: 10.7573/dic.2024-1-6.

Use of Topical Corticosteroids in the Treatment of Noninfectious Inflammatory Dermatoses of the Scalp: A Survey of Practicing Dermatologists and Dermatology Residents Using Delphi Methodology.

Mir-Bonafe J, Piquero-Casals J, Prudkin L, Delgado J, Martinez J, Briones V Clin Cosmet Investig Dermatol. 2024; 17:671-681.

PMID: 38524395 PMC: 10959751. DOI: 10.2147/CCID.S448016.

An Overview of Contemporary and Future Therapeutic Strategies for Scalp Psoriasis.

Soni B, Shivgotra R, Trehan K, Chhina A, Saini M, Jain S Curr Drug Targets. 2024; 25(5):353-373.

PMID: 38500274 DOI: 10.2174/0113894501292755240304063020.

References

Lebwohl M, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley R . Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014; 70(5):871-81.e1-30. DOI: 10.1016/j.jaad.2013.12.018. View

Roelofzen J, Aben K, Oldenhof U, Coenraads P, Alkemade H, van de Kerkhof P . No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J Invest Dermatol. 2009; 130(4):953-61. DOI: 10.1038/jid.2009.389. View

Langley R, Rich P, Menter A, Krueger G, Goldblum O, Dutronc Y . Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2015; 29(9):1763-70. DOI: 10.1111/jdv.12996. View

Mahrle G, Bonnekoh B, Wevers A, Hegemann L . Anthralin: how does it act and are there more favourable derivatives?. Acta Derm Venereol Suppl (Stockh). 1994; 186:83-4. View

Reichrath J, Muller S, Kerber A, Baum H, Bahmer F . Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol. 1997; 36(1):19-28. DOI: 10.1016/s0190-9622(97)70320-7. View

Luger T, Cambazard F, Larsen F, Bourcier M, Gupta G, Clonier F . A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology. 2008; 217(4):321-8. PMC: 2790732. DOI: 10.1159/000155642. View

Chan C, Van Voorhees A, Lebwohl M, Korman N, Young M, Bebo Jr B . Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009; 60(6):962-71. DOI: 10.1016/j.jaad.2008.11.890. View

Mason A, Mason J, Cork M, Hancock H, Dooley G . Topical treatments for chronic plaque psoriasis of the scalp: a systematic review. Br J Dermatol. 2013; 169(3):519-27. DOI: 10.1111/bjd.12393. View

Spuls P, Lecluse L, Poulsen M, Bos J, Stern R, Nijsten T . How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010; 130(4):933-43. DOI: 10.1038/jid.2009.391. View

10.

van der Vleuten C, van de Kerkhof P . Management of scalp psoriasis: guidelines for corticosteroid use in combination treatment. Drugs. 2001; 61(11):1593-8. DOI: 10.2165/00003495-200161110-00006. View

11.

Papp K, Berth-Jones J, Kragballe K, Wozel G, De La Brassinne M . Scalp psoriasis: a review of current topical treatment options. J Eur Acad Dermatol Venereol. 2007; 21(9):1151-60. DOI: 10.1111/j.1468-3083.2007.02424.x. View

12.

Barnes L, Altmeyer P, Forstrom L, Stenstrom M . Long-term treatment of psoriasis with calcipotriol scalp solution and cream. Eur J Dermatol. 2000; 10(3):199-204. View

13.

Menter A, Gottlieb A, Feldman S, Van Voorhees A, Leonardi C, Gordon K . Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008; 58(5):826-50. DOI: 10.1016/j.jaad.2008.02.039. View

14.

Rich P, Gooderham M, Bachelez H, Goncalves J, Day R, Chen R . Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2015; 74(1):134-42. DOI: 10.1016/j.jaad.2015.09.001. View

15.

Kalb R, Blauvelt A, Sofen H, Chevrier M, Amato D, Calabro S . Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial. J Drugs Dermatol. 2013; 12(8):874-80. View

16.

Taneja A, Racette A, Gourgouliatos Z, Taylor C . Broad-band UVB fiber-optic comb for the treatment of scalp psoriasis: a pilot study. Int J Dermatol. 2004; 43(6):462-7. DOI: 10.1111/j.1365-4632.2004.01993.x. View

17.

Di Cesare A, Fargnoli M, Peris K . Rapid response of scalp psoriasis to ustekinumab. Eur J Dermatol. 2011; 21(6):993-4. DOI: 10.1684/ejd.2011.1499. View

18.

van de Kerkhof P, Franssen M . Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol. 2001; 2(3):159-65. DOI: 10.2165/00128071-200102030-00005. View

19.

Mazzotta A, Esposito M, Carboni I, Schipani C, Chimenti S . Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. J Dermatolog Treat. 2007; 18(2):84-7. DOI: 10.1080/09546630601123835. View

20.

Crowley J . Scalp psoriasis: an overview of the disease and available therapies. J Drugs Dermatol. 2010; 9(8):912-8. View